Introduction
There's an important distinction that gets lost in a lot of conversation about "AI and regulatory affairs": regulating AI-enabled products, like software as a medical device or AI-assisted diagnostics, is a different subject from regulatory affairs professionals using AI tools to do their own jobs. This article is about the second thing. Drafting assistance, literature searching, document comparison, and submission assembly are all areas where AI-powered tools are showing up in regulatory teams' day-to-day workflow, and the practical questions worth understanding are what these tools are actually good at, where they fall short, and what that means for how the role itself is evolving.
Where AI Tools Are Actually Being Used
The most mature use case right now is drafting assistance for structured, template-driven document sections — things like standard operating procedures, certain sections of a Common Technical Document (CTD) module, or first-pass summaries of clinical or nonclinical data that a regulatory writer then substantially edits. These tools are useful as a starting point generator, not a replacement for the judgment that goes into deciding what a submission section should actually argue and how it should be structured to anticipate a reviewer's questions.
Literature and guidance searching is another area seeing real adoption. Instead of manually searching FDA guidance documents, warning letters, or published literature one query at a time, regulatory professionals are increasingly using AI-assisted search tools that can surface relevant precedent faster. The caveat is significant, though: these tools can miss context, misstate a regulation's actual requirement, or cite guidance that has since been updated or withdrawn, so nothing surfaced this way should go into a submission without independent verification against the primary source.
Document comparison and change tracking is a quieter but genuinely useful application — comparing a new draft against a previously approved version, or checking a submission against a checklist of required elements, is a task well suited to tools that are good at pattern matching across large documents, and this is an area where the risk of an AI tool's errors is lower because a human is still verifying the underlying comparison rather than trusting a generated conclusion outright.
Where These Tools Fall Short
Regulatory writing is fundamentally an exercise in persuasion under a specific, evolving set of rules, and current AI tools are not reliably good at understanding which specific argument will land with a specific reviewer or agency, especially when guidance is ambiguous or precedent is thin. They also don't have real accountability for being wrong — if an AI-generated summary misrepresents a safety signal or omits a required element, the regulatory professional who submitted it is accountable, not the tool. This is why virtually every serious deployment of these tools in regulated environments keeps a qualified human reviewer in the loop for anything that will actually be submitted to an agency, rather than treating tool output as submission-ready.
There's also a data sensitivity issue that regulatory teams have to take seriously. Submission content often includes confidential manufacturing details, unpublished clinical data, and other information that cannot be run through a public, consumer-facing AI tool without violating confidentiality obligations and potentially the company's own data governance policies. Companies adopting these tools for regulatory work are generally doing so through enterprise deployments with contractual data protections, not through general-purpose consumer AI products, and any regulatory professional experimenting with these tools should understand their employer's policy before running real submission content through any AI system.
What This Means for the Regulatory Affairs Role
The tasks most likely to be meaningfully assisted by AI tools are the ones that were already the least differentiating parts of the job: first-pass drafting of highly templated content, initial literature scans, and mechanical formatting or comparison checks. The tasks that remain squarely human are the ones that were always the actual value of a senior regulatory professional — deciding what regulatory strategy to pursue, judging how an agency is likely to react to a given approach, negotiating directly with reviewers, and taking accountability for what goes into a submission. If anything, tools that speed up the mechanical work should, in principle, free up more time for that higher-judgment work, though whether that time actually gets reallocated that way depends heavily on how individual teams and companies choose to use the tools.
How This Shows Up Inside Existing Systems
For most regulatory teams, AI capability isn't arriving as a standalone tool the team goes out and adopts on its own — it's increasingly arriving as a feature bolted onto systems the team already uses, particularly regulatory information management (RIM) platforms and document management systems that handle submission publishing and tracking. This matters practically: it means many regulatory professionals will encounter AI-assisted features first through a vendor update to an existing platform rather than through a deliberate new tool rollout, and it's worth paying attention to release notes and internal training when those features land rather than assuming a familiar system hasn't changed. It also means IT, quality, and regulatory operations teams are often the ones deciding how a given AI feature gets configured and validated before regulatory affairs staff ever see it, so understanding your organization's validation and change-control process for these systems is relevant even if you're not the one making the adoption decision.
Validation and Documentation Considerations
Companies operating under good practice quality systems generally need to validate software tools used in regulated work, and AI-assisted features inside a validated system raise real questions about how that validation is maintained when the underlying AI model itself might be updated by the vendor outside the company's control. This is a genuinely unresolved area of practice across the industry right now, with different companies taking different, reasonable approaches — some restrict AI features to non-GxP-impacting tasks only, others require re-validation triggers tied to vendor model updates. Regulatory affairs professionals don't need to personally resolve this tension, but understanding that it exists, and that your quality and IT colleagues are actively working through it, helps explain why AI feature rollout inside regulated companies tends to move more cautiously than the broader tech industry's pace of AI adoption.
Skills Worth Building in Response
Rather than treating AI tools as a threat to learn to compete against, the more useful posture is learning to use them well and to verify their output critically. That means understanding enough about how these tools generate text to know where they're likely to be unreliable — for instance, they can produce fluent, confident-sounding text about a regulation that doesn't actually say what the tool claims. Being able to quickly and accurately spot that kind of error is becoming a genuinely valuable skill, not a niche one. It's also worth building familiarity with whatever enterprise tools your own company or a target employer has adopted, since fluency with the specific platform in use is increasingly a practical, screenable skill in interviews for some regulatory roles, particularly at larger organizations that have made meaningful investments in this infrastructure.
What Hiring Managers Are Watching For
Some regulatory hiring managers are beginning to ask candidates how they think about using AI tools responsibly in submission work, less to test specific tool fluency and more to gauge judgment — whether a candidate understands that these tools need verification, confidentiality handling, and human accountability, or whether they'd treat generated output as trustworthy by default. A candidate who can speak concretely about where they've used these tools productively, and where they've caught a tool getting something wrong, tends to come across as more credible than one who either dismisses the tools entirely or describes using them uncritically.
What Smaller Companies Face Differently
Large pharmaceutical and device companies generally have the resources to build or license enterprise AI tools with proper data governance and validation controls, along with dedicated regulatory operations and IT staff to manage the rollout. Smaller biotech and device companies often don't have that infrastructure, which puts regulatory professionals at smaller organizations in a harder position: the productivity case for using AI tools is just as real, but the governance and data protection safeguards may be thinner or nonexistent. In practice, this often means regulatory professionals at smaller companies have to be more personally conservative about what they'll run through any AI tool, and more proactive about raising data governance questions with leadership, since there may not be a dedicated function already doing that work on the team's behalf.
A Reasonable Way to Start
For regulatory professionals who haven't yet incorporated these tools into their workflow, a reasonable starting point is low-stakes, easily verified tasks: using an AI tool to draft a first pass of an internal document you'll heavily edit anyway, or to help organize a literature search you'll independently verify, rather than starting with anything that goes directly into a regulatory submission. Building comfort and calibrated trust — knowing specifically where a given tool tends to be reliable and where it tends to make mistakes — over time on lower-stakes work is a more sustainable path than either avoiding the tools entirely or adopting them uncritically for high-stakes work from day one.
Conclusion
AI tools are changing parts of day-to-day regulatory affairs work, but the change is more incremental and task-specific than the broader hype around AI suggests. The tools are genuinely useful for first-pass drafting, literature searching, and document comparison, and genuinely unreliable for regulatory judgment and strategy — and treating those two categories as distinct is the single most important thing a regulatory professional can do when deciding how to use them. The professionals who benefit most from this shift will likely be the ones who learn to use these tools critically, verify their output rigorously, and redirect the time saved toward the strategic and judgment-based work that has always been the actual core of the regulatory affairs role.